Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:COCH

Envoy Medical Q3 2026 Earnings Date & Estimates

Envoy Medical logo
$6.51 +0.01 (+0.15%)
Closing price 04:00 PM Eastern
Extended Trading
$6.56 +0.04 (+0.69%)
As of 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Envoy Medical is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for November 10, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Envoy Medical in Q3 2026

Envoy Medical is expected to post earnings of -$0.07 per share on revenue of $85 thousand. In the same quarter a year earlier Envoy Medical reported -$3.50 per share on revenue of $42 thousand. Envoy Medical last reported on August 10, 2026, posting -$0.70 per share and beating the -$0.80 consensus estimate. Envoy Medical has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.07
Expected Revenue
$85 thousand
Prior-Year EPS
-$3.50
Prior-Year Revenue
$42 thousand
Expected Revenue Growth
+102.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.70 (Beat by +$0.10)
Last Quarter Revenue
$51 thousand
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Envoy Medical Q3 2026 Earnings FAQ

Envoy Medical (NASDAQ:COCH) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Envoy Medical's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Envoy Medical to post earnings of -$0.07 per share for Q3 2026.

The consensus revenue estimate for Envoy Medical is $85 thousand for Q3 2026.

Envoy Medical Earnings Headlines

Envoy Medical, Inc. announces 1-for-10 reverse stock split
 |  msn.comhttps://www.msn.com/en-us/money/top-stocks/envoy-medical-inc-announces-1-for-10-reverse-stock-split/ar-AA2gbu2U
Envoy Medical (NASDAQ:COCH) vs. DENTSPLY SIRONA (NASDAQ:XRAY) Critical Contrast
October 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31128576
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.tc pixel
October 27 at 1:00 AM  |  Base Camp Trading (Ad)
Envoy Medical Shareholders Approve Reverse Stock Split Plan
October 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/envoy-medical-shareholders-approve-reverse-stock-split-plan?utm_source=marketbeat.com&utm_medium=referral
Analysts Offer Insights on Healthcare Companies: Envoy Medical (COCH) and CVS Health (CVS)
October 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CVS/pressreleases/7556215/analysts-offer-insights-on-healthcare-companies-envoy-medical-coch-and-cvs-health-cvs/
Envoy Medical Resolves SPAC Litigation, Strengthening Legal Position
October 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/envoy-medical-resolves-spac-litigation-strengthening-legal-position?utm_source=marketbeat.com&utm_medium=referral
See More Envoy Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Envoy Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Envoy Medical and other key companies, straight to your email.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) is a medical technology company focused on developing fully implanted hearing devices for people with sensorineural hearing loss. Unlike conventional hearing aids and many cochlear implants, its technology is designed to be placed beneath the skin, with no external wearable sound processor.

The company’s lead product is the Acclaim Cochlear Implant, a fully implanted cochlear implant intended to address moderate-to-profound sensorineural hearing loss in adults. The system is designed to use the body’s natural anatomy to capture sound and convert it into electrical signals that stimulate the auditory nerve. Envoy Medical has also developed the Esteem Fully Implanted Active Middle Ear Implant, an earlier device based on similar fully implanted hearing technology.

Envoy Medical is headquartered in White Bear Lake, Minnesota, and has focused primarily on the U.S. hearing-loss treatment market. The company was founded in 1995 and became publicly traded in 2023. Brent Lucas serves as chief executive officer. Its Acclaim system has been evaluated through clinical development and regulatory processes as the company works toward broader commercialization.

View Envoy Medical Profile
Earnings Tools